Sentiment-Signal
15,1
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (23.03.2026)
HOCH Abgang Schlüsselpersonen (23.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 23.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 06.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 21.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 10.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Unternehmen & Branche
| Name | Arcus Biosciences, Inc. |
|---|---|
| Ticker | RCUS |
| CIK | 0001724521 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,43 Mrd. USD |
| Beta | 0,86 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 247,000,000 | -353,000,000 | -3.29 | 1,139,000,000 | 631,000,000 |
| 2025-09-30 | 10-Q | 26,000,000 | -135,000,000 | -1.27 | 974,000,000 | 436,000,000 |
| 2025-06-30 | 10-Q | 160,000,000 | 0 | 0.00 | 1,075,000,000 | 549,000,000 |
| 2025-03-31 | 10-Q | 28,000,000 | -112,000,000 | -1.14 | 1,156,000,000 | 531,000,000 |
| 2024-12-31 | 10-K | 258,000,000 | -283,000,000 | -3.14 | 1,150,000,000 | 485,000,000 |
| 2024-09-30 | 10-Q | 48,000,000 | -92,000,000 | -1.00 | 1,252,000,000 | 565,000,000 |
| 2024-06-30 | 10-Q | 39,000,000 | -93,000,000 | -1.02 | 1,186,000,000 | 635,000,000 |
| 2024-03-31 | 10-Q | 145,000,000 | -4,000,000 | -0.05 | 1,293,000,000 | 707,000,000 |
| 2023-12-31 | 10-K | 117,000,000 | -307,000,000 | -4.15 | 1,095,000,000 | 462,000,000 |
| 2023-09-30 | 10-Q | 32,000,000 | -71,000,000 | -0.94 | 1,191,000,000 | 520,000,000 |
| 2023-06-30 | 10-Q | 29,000,000 | -75,000,000 | -1.04 | 1,220,000,000 | 566,000,000 |
| 2023-03-31 | 10-Q | 25,000,000 | -80,000,000 | -1.09 | 1,254,000,000 | 600,000,000 |
| 2022-12-31 | 10-K | 112,000,000 | -267,000,000 | -3.71 | 1,345,000,000 | 657,000,000 |
| 2022-09-30 | 10-Q | 33,000,000 | -65,000,000 | -0.90 | 1,393,822,000 | 699,000,000 |
| 2022-06-30 | 10-Q | 27,000,000 | -67,000,000 | 1,476,773,000 | 747,000,000 | |
| 2022-03-31 | 10-Q | 18,000,000 | -68,000,000 | 1,543,427,000 | 797,000,000 | |
| 2021-12-31 | 10-K | 383,000,000 | 53,000,000 | 0.71 | 1,592,000,000 | 842,000,000 |
| 2021-09-30 | 10-Q | 9,461,000 | -77,975,000 | -1.11 | 839,290,000 | 542,607,000 |
| 2021-06-30 | 10-Q | 9,461,000 | -75,970,000 | 898,773,000 | 604,555,000 | |
| 2021-03-31 | 10-Q | 9,461,000 | -72,593,000 | 935,119,000 | 664,790,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | Jaen Juan C. | Officer, President | Open Market Sale | -29,670 | 21.34 | -633,157.80 | -204,0% | |
| 2026-01-05 | Jaen Juan C. | Officer, President | Open Market Sale | -2,053 | 22.34 | -45,864.02 | -14,8% | |
| 2026-01-05 | Jaen Juan C. | Officer, President | Open Market Sale | -100 | 23.20 | -2,320.00 | -0,7% | |
| 2025-12-31 | Goeltz II Robert C. | Officer, Chief Financial Officer | Open Market Sale | -6,552 | 23.38 | -153,185.76 | -49,4% | |
| 2025-12-18 | Azoy Alexander | Officer, Chief Accounting Officer | Open Market Sale | -4,343 | 22.25 | -96,613.51 | -31,1% | |
| 2025-12-17 | Tang Carolyn C. | Officer, General Counsel | Open Market Sale | -6,810 | 22.16 | -150,906.20 | -48,6% | |
| 2025-12-17 | Goeltz II Robert C. | Officer, Chief Financial Officer | Open Market Sale | -5,960 | 22.16 | -132,070.62 | -42,6% | |
| 2025-12-17 | ROSEN TERRY J | Director, Officer, Chief Executive Officer | Open Market Sale | -25,744 | 22.16 | -570,474.17 | -183,8% | |
| 2025-12-17 | Markus Richard | Officer, Chief Medical Officer | Open Market Sale | -4,494 | 22.16 | -99,584.79 | -32,1% | |
| 2025-12-17 | Jarrett Jennifer | Officer, Chief Operating Officer | Open Market Sale | -9,983 | 22.16 | -221,218.29 | -71,3% | |
| 2025-12-17 | Azoy Alexander | Officer, Chief Accounting Officer | Open Market Sale | -2,113 | 22.16 | -46,823.02 | -15,1% | |
| 2025-12-17 | Jaen Juan C. | Officer, President | Open Market Sale | -9,983 | 22.16 | -221,218.29 | -71,3% | |
| 2025-12-16 | Jarrett Jennifer | Officer, Chief Operating Officer | Open Market Sale | -11,225 | 21.88 | -245,651.27 | -79,2% | |
| 2025-12-16 | Goeltz II Robert C. | Officer, Chief Financial Officer | Open Market Sale | -6,702 | 21.88 | -146,668.58 | -47,3% | |
| 2025-12-16 | Jaen Juan C. | Officer, President | Open Market Sale | -11,225 | 21.88 | -245,651.27 | -79,2% | |
| 2025-12-16 | ROSEN TERRY J | Director, Officer, Chief Executive Officer | Open Market Sale | -28,947 | 21.88 | -633,484.83 | -204,1% | |
| 2025-12-16 | Markus Richard | Officer, Chief Medical Officer | Open Market Sale | -5,052 | 21.88 | -110,559.48 | -35,6% | |
| 2025-12-16 | Tang Carolyn C. | Officer, General Counsel | Open Market Sale | -7,658 | 21.88 | -167,589.97 | -54,0% | |
| 2025-12-16 | Azoy Alexander | Officer, Chief Accounting Officer | Open Market Sale | -2,376 | 21.88 | -51,997.10 | -16,8% | |
| 2025-12-04 | Jaen Juan C. | Officer, President | Open Market Sale | -82,997 | 24.71 | -2,050,598.58 | -660,8% | |
| 2025-11-26 | Goeltz II Robert C. | Officer, Chief Financial Officer | Open Market Sale | -5,000 | 25.00 | -125,000.00 | -40,3% | |
| 2025-11-26 | Azoy Alexander | Officer, Chief Accounting Officer | Open Market Sale | -1,900 | 26.00 | -49,400.00 | -15,9% | |
| 2025-11-18 | Jaen Juan C. | Officer, President | Open Market Sale | -5,050 | 19.75 | -99,737.50 | -32,1% | |
| 2025-11-17 | Jaen Juan C. | Officer, President | Open Market Sale | -37,114 | 20.23 | -750,719.72 | -241,9% | |
| 2025-11-17 | Jaen Juan C. | Officer, President | Open Market Sale | -7,836 | 20.71 | -162,307.07 | -52,3% | |
| 2025-11-07 | Jarrett Jennifer | Officer, Chief Operating Officer | Open Market Sale | -50,291 | 18.97 | -954,065.53 | -307,5% | |
| 2025-10-30 | Jaen Juan C. | Officer, President | Open Market Sale | -4,314 | 20.32 | -87,649.70 | -28,2% | |
| 2025-10-29 | Jaen Juan C. | Officer, President | Open Market Sale | -800 | 22.04 | -17,635.28 | -5,7% | |
| 2025-10-29 | Jaen Juan C. | Officer, President | Open Market Sale | -29,365 | 21.53 | -632,166.78 | -203,7% | |
| 2025-10-29 | Jaen Juan C. | Officer, President | Open Market Sale | -47,675 | 20.49 | -976,832.15 | -314,8% | |
| 2025-10-28 | Goeltz II Robert C. | Officer, Chief Financial Officer | Open Market Sale | -5,000 | 20.00 | -100,000.00 | -32,2% | |
| 2025-10-28 | Jaen Juan C. | Officer, President | Open Market Sale | -19,019 | 20.19 | -383,944.16 | -123,7% | |
| 2025-10-08 | Jarrett Jennifer | Officer, Chief Operating Officer | Open Market Sale | -37,792 | 15.05 | -568,610.87 | -183,2% | |
| 2025-10-06 | Jarrett Jennifer | Officer, Chief Operating Officer | Open Market Sale | -12,500 | 14.54 | -181,801.25 | -58,6% | |
| 2025-09-29 | Azoy Alexander | Officer, Chief Accounting Officer | Open Market Sale | -2,831 | 13.00 | -36,803.00 | -11,9% | |
| 2025-09-05 | Azoy Alexander | Officer, Chief Accounting Officer | Open Market Sale | -1,579 | 11.88 | -18,758.05 | -6,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.